Technology
Health
Biotechnology

Ligand Pharmaceuticals

$112.36
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.45 (-2.13%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell LGND and other stocks, options, ETFs, and crypto commission-free!

About

Ligand Pharmaceuticals Incorporated Common Stock, also called Ligand Pharmaceuticals, is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. Read More The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Employees
116
Headquarters
San Diego, California
Founded
1987
Market Cap
2.26B
Price-Earnings Ratio
3.20
Dividend Yield
0.00
Average Volume
534.68K
High Today
$114.27
Low Today
$111.07
Open Price
$113.84
Volume
77.20K
52 Week High
$278.62
52 Week Low
$98.56

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
US
North America

News

Yahoo FinanceMay 14

Ligand Pharmaceuticals Inc CEO John L Higgins Bought $283,750 of Shares

- By insider CEO of Ligand Pharmaceuticals Inc (LGND) John L Higgins bought 2,500 shares of LGND on 05/14/2019 at an average price of $113.5 a share. The total cost of this purchase was $283,750. Ligand Pharmaceuticals Inc is a biopharmaceutical company. Its business model is based upon the concept of acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand Pharmaceuticals Inc has a market cap of $2.21 billion; its shares were traded at around $112.60 ...

155
Associated PressMay 6

Novan Completes Funding Transaction with Ligand Pharmaceuticals

-- Novan to immediately receive $12 million of non-dilutive capital -- Ligand to receive milestones and tiered royalty for North America SB206 molluscum indication -- Phase 3 molluscum trial to begin recruitment of patients this month -- Molluscum top line results targeted early during the first quarter of 2020 or before MORRISVILLE, N.C., May 06, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company has secured $12 million in non-dilutive capital fr...

101
Yahoo FinanceMay 6

Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.

SAN DIEGO--(BUSINESS WIRE)-- Phase 3 drug candidate targeting molluscum Ligand Pharmaceuticals Incorporated (LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections, including molluscum contagiosum. Ligand will pay $12 million to Novan and in return will be entitled to receive a tiered royalty of 7% to 10%, as well as up to $20 million in regulatory and commercial milestones. Novan is responsible for all exp...

238

Earnings

$0.61
$1.27
$1.93
$2.59
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 5, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.